(R) -SL18

(R) -SL18 is a degrader of ANXA3 and can degrade ANXA3 protein through the ubiquitination pathway. (R) -SL18 inhibits the proliferation, migration, invasion, and colony formation of breast cancer cells and induces apoptosis. (R) -SL18 can be used in the research of triple-negative breast cancer[1].

Product Specifications

CAS Number

[3023189-40-1]

UNSPSC

12352101

Target

Annexin A; Apoptosis

Related Pathways

Apoptosis; Cytoskeleton

Field of Research

Cancer

Smiles

CN1C2=CC=CC=C2C(C3=CC=CC=C3)=N[C@@H](NC(SCC(NC(NC4=CC(Cl)=CC=C4[N+]([O-])=O)=O)=O)=S)C1=O

Molecular Formula

C26H21ClN6O5S2

Molecular Weight

597.07

References & Citations

[1]Liu K, et al. Discovery of a Novel 1,4-Benzodiazepine Derivative as a Highly Selective ANXA3 Degrader for the Treatment of Triple-Negative Breast Cancer. J Med Chem. 2025 Feb 27.